W
Winald R. Gerritsen
Researcher at Radboud University Nijmegen
Publications - 197
Citations - 9214
Winald R. Gerritsen is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 33, co-authored 179 publications receiving 6672 citations. Previous affiliations of Winald R. Gerritsen include Radboud University Nijmegen Medical Centre & VU University Medical Center.
Papers
More filters
Journal ArticleDOI
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt,Ronald de Wit,David J. Vaughn,Yves Fradet,Jae-Lyun Lee,Lawrence Fong,Nicholas J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Yabing Mai,Christian Heinrich Poehlein,Rodolfo F. Perini,Dean F. Bajorin +19 more
TL;DR: Pembrolizumab was associated with significantly longer overall survival and with a lower rate of treatment‐related adverse events than chemotherapy as second‐line therapy for platinum‐refractory advanced urothelial carcinoma.
Journal ArticleDOI
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon,Charles G. Drake,Howard I. Scher,Karim Fizazi,Alberto Bossi,Alfons J.M. van den Eertwegh,Michael Krainer,Nadine Houede,Ricardo Santos,Hakim Mahammedi,Siobhan Ng,Michele Maio,Fabio Franke,Santhanam Sundar,Neeraj Agarwal,Andries M. Bergman,Tudor Ciuleanu,Ernesto Korbenfeld,Lisa Sengeløv,Steinbjørn Hansen,Christopher J. Logothetis,Tomasz M. Beer,M. Brent McHenry,Paul Gagnier,David R. Liu,Winald R. Gerritsen +25 more
TL;DR: There was no significant difference between the ipilimumab group and the placebo group in terms of overall survival in the primary analysis, but there were signs of activity with the drug that warrant further investigation.
Journal ArticleDOI
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer,Eugene D. Kwon,Charles G. Drake,Karim Fizazi,Christopher J. Logothetis,Gwenaelle Gravis,Vinod Ganju,Jonathan Polikoff,Fred Saad,Piotr Humanski,Josep M. Piulats,Pablo González Mella,Siobhan Ng,Dirk Jaeger,Francis Parnis,Fabio Franke,J. Puente,Roman Carvajal,Lisa Sengeløv,M. Brent McHenry,Arvind Varma,Alfonsus J. M. van den Eertwegh,Winald R. Gerritsen +22 more
TL;DR: Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer and the observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
Journal ArticleDOI
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Yves Fradet,Joaquim Bellmunt,David J. Vaughn,J.-L. Lee,Lawrence Fong,N. J. Vogelzang,Miguel Angel Climent,Daniel P. Petrylak,Toni K. Choueiri,Andrea Necchi,Winald R. Gerritsen,Howard Gurney,David I. Quinn,Stéphane Culine,Cora N. Sternberg,Kijoeng Nam,Tara L. Frenkl,Rodolfo F. Perini,R. de Wit,Dean F. Bajorin +19 more
TL;DR: Long-term results (>2 years’ follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally advanced/metastatic, platinum-refractory UC.
Journal ArticleDOI
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
TL;DR: To allow meaningful multicenter phase III trials, the production of DC vaccines should be standardized between centers which is now becoming feasible, and to improve the efficacy of DC-based immunotherapy, it could be combined with other treatments.